Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature Review
International Journal of Neonatal Screening · 05.11.2025 · 11 (4) · 103
DOI: 10.3390/ijns11040103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 05.11.2025. Verfasst von Lucia Laugwitz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neuropaediatrics, General Paediatrics, Diabetology, Endocrinology and Social Paediatrics, University Hospital Tübingen, University of Tübingen, 72076…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Orchard Therapeutics.
Abstract (Originalsprache)
A systematic literature review was conducted to evaluate the emerging evidence on newborn screening (NBS) for metachromatic leukodystrophy (MLD; MIM #250100). The review focuses on (1) screening assay performance, (2) diagnostic confirmation methods and care pathways, (3) feasibility of population-based identification, and (4) the impact of early diagnosis and treatment on health outcomes. Electronic databases were searched in February 2025, and supplementary searches were performed up to 17 June 2025, for articles referencing NBS for MLD and treatments for MLD; 52 publications were eligible for inclusion. Nationwide NBS for MLD is currently carried out in Norway and large prospective pilots are running in Germany, Austria, Italy and the US. MLD meets established Wilson and Jungner criteria, with a reliable screening algorithm, established confirmatory diagnostics, and actionable care pathways. There is ongoing work to develop tools to predict disease severity and subtype. Early intervention—via gene therapy for early-onset MLD and hematopoietic stem cell transplantation (HSCT) for late-onset forms—significantly improves outcomes when initiated before symptom onset. This review provides the first comprehensive synthesis of the evidence supporting MLD for inclusion in NBS programs, underscoring the public health value of early identification and intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuropaediatrics, General Paediatrics, Diabetology, Endocrinology and Social Paediatrics, University Hospital Tübingen, University of Tübingen, 72076 Tübingen, Germany.
- Independent Clinical Consultant, Pennington, NJ 08534, USA.
- And You SARL, 1260 Nyon, Switzerland.
- Oxford PharmaGenesis, Oxford OX13 5QJ, UK.
- Independent Clinical Consultant, Cape Elizabeth, ME 04107, USA.
- Orchard Therapeutics, London W6 8PW, UK.
ORCID-Profile: Lucia Laugwitz, Stéphane Pintat, David Whiteman
Förderung
- Orchard Therapeutics
Zitieren
APA
Laugwitz, L., Shenker, A., Sluys, E. F., Pintat, S., Whiteman, D., & Chanson, C. (2025). Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature Review. International Journal of Neonatal Screening, 11(4), 103. https://doi.org/10.3390/ijns11040103
Vancouver
Laugwitz L, Shenker A, Sluys EF, Pintat S, Whiteman D, Chanson C. Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature Review. International Journal of Neonatal Screening. 2025;11(4):103. doi:10.3390/ijns11040103
BibTeX
@article{Laugwitz2025,
author = {Laugwitz, Lucia and Shenker, Andrew and Sluys, Erica F and Pintat, Stéphane and Whiteman, David and Chanson, Charlotte},
title = {Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature Review},
journal = {International Journal of Neonatal Screening},
year = {2025},
volume = {11},
number = {4},
pages = {103},
doi = {10.3390/ijns11040103}
}
EUVIMED